Evidence map›Paper›PMID 29800309›Full record

Trial reportThe Journal of infectious diseases2018

Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.

Catia T Perciani, Manmeet Sekhon, Sabrina Hundal, Bashir Farah, Mario A Ostrowski, A Omu Anzala, Lyle R McKinnon, Walter Jaoko, Kelly S MacDonald, Institute of Tropical and Infectious Diseases (UNITID) Group and the Kenyan AIDS Vaccine Initiative–Institute of Clinical Research (KAVI-ICR) Team

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02514018 (A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya.), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02514018 phase4unknown statusnot on this map

A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya.

TypeinterventionalSponsorUniversity of TorontoRan2015 to 2017Enrolled45ConditionsHealthyArmsLive-attenuated varicella-zoster virus vaccine
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Effect of water immersion restraint stress on gastric mucosa in rats with removed salivary glands.International journal of clinical and experimental pathology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Catia T PercianiDepartment of Immunology, University of Toronto, Ontario, Canada.
Manmeet SekhonDepartment of Immunology, University of Toronto, Ontario, Canada.
Sabrina HundalDepartment of Immunology, University of Toronto, Ontario, Canada.
Bashir FarahKenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.
Mario A OstrowskiDepartment of Immunology, University of Toronto, Ontario, Canada.
A Omu AnzalaKenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.
Lyle R McKinnonDepartment of Medical Microbiology, University of Nairobi, Kenya.
Walter JaokoKenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.
Kelly S MacDonaldDepartment of Immunology, University of Toronto, Ontario, Canada.
Institute of Tropical and Infectious Diseases (UNITID) Group and the Kenyan AIDS Vaccine Initiative–Institute of Clinical Research (KAVI-ICR) Team
Kenya AIDS Vaccine Initiative · KEUniversity of Toronto · CAUniversity of Nairobi · KESt. Michael's Hospital · CA

Funding

CIHR THA-11960
6 · The paper itself

Abstract

Background: Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immunodeficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZVOka vaccination. Methods: Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288). Results: Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P < .0001) and 1.6-fold rise in immunoglobulin A (IgA) (P = .004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection. Conclusions: VZVOka vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity. Clinical Trials Registration: NCT02514018.

Indexed as

Immunity, HumoralAntibodies, ViralFemaleHerpesvirus 3, HumanHerpes Zoster VaccineHumansKenyaMucous MembraneVaccines, AttenuatedVaginaVaricella Zoster Virus InfectionAntibodies, ViralHerpes Zoster VaccineVaccines, Attenuated

Identifiers

PMID29800309
PMCPMC6129112
OpenAlexW2809288644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.